Deals channel feed

As­traZeneca puts down $185M up­front for PhI oral GLP-1 as it shoots for next-gen win

Last year
R&D

BioN­Tech’s ‘ex­ten­sive’ can­cer pipeline comes in­to fo­cus, with em­pha­sis on AD­Cs

Last year
R&D

Bio­gen CEO seeks 'aw­ful lot more col­lab­o­ra­tions' to beef up R&D as it launch­es post­par­tum de­pres­sion, Alzheimer's and ALS drugs

Last year
Pharma

No­var­tis slots PhI car­dio­vas­cu­lar can­di­date in­to pipeline, pay­ing Ko­re­an part­ner $80M up­front

Last year
R&D

Dutch-US biotech rais­es $61M to test ex-Mit­subishi Tan­abe drug for schiz­o­phre­nia

Last year
Financing
Startups

Up­dat­ed: Cel­lares to pro­duce Ca­balet­ta’s au­toim­mune CAR-T can­di­date 

Last year
Manufacturing

BioN­Tech grabs PD-L1/VEGF bis­pe­cif­ic with $55M up­front, ex­pand­ing pipeline while low­er­ing Covid guid­ance

Last year
China

Bris­tol My­ers buys Orum Ther­a­peu­tic­s' pro­tein de­grad­er take on AD­Cs for $100M up­front

Last year
Startups
Pharma

Star­ton Ther­a­peu­tics scraps SPAC deal that would have tak­en it pub­lic, brought in $50M

Last year

Ex­clu­sive: BioN­Tech ac­quires lipid nanopar­ti­cle start­up found­ed by George Ma­son and UPenn sci­en­tists

Last year

With IPO mon­ey, Neumo­ra eyes deals as CEO brings M&A chops from roles at Ab­b­Vie, JP Mor­gan

Last year

Ab­b­Vie seeks Resta­sis fol­low-up with small op­tion fee for Aldeyra’s eye drops, de­spite a po­ten­tial 'im­mi­nen­t' CRL

Last year
Pharma

As­traZeneca pays $25M up­front, $80M eq­ui­ty in­vest­ment in­to Cel­lec­tis for gene and cell ther­a­py pact

Last year
Cell/Gene Tx

Gen­er­a­tive AI biotech part­ners with can­cer cen­ter in bid to speed up CAR-T de­vel­op­ment in sol­id tu­mors

Last year
AI
Cell/Gene Tx

Ap­n­imed and Sh­iono­gi cre­ate $150M joint ven­ture for sleep ap­nea

Last year
Financing
Pharma

GSK steps in for J&J’s li­cense of Ar­row­head’s he­pati­tis B drug, plans com­bo study with its own can­di­date

Last year
R&D
Pharma

Kite en­lists Epic Bio to ap­ply epi­ge­net­ic edit­ing in cre­at­ing next-gen CAR-T cells

Last year
Cell/Gene Tx

Gala­pa­gos plans to hand over Jy­s­e­le­ca and 400 em­ploy­ees to Al­fasig­ma, re­duce work­force by 100

Last year
People
Pharma

Lil­ly makes an­oth­er move for Verve's ge­net­ic med­i­cines, this time buy­ing Beam's opt-in rights

Last year
Pharma
Cell/Gene Tx

Mer­ck KGaA pays $169M up­front in deal for Hen­grui’s PARP1 in­hibitor and ADC

Last year
R&D

Deal flow in­flux: Abing­worth's new $356M fund will help Big Phar­ma ex­pand drug la­bels

Last year
Financing
Pharma

Ac­cen­ture boosts life sci­ences mar­ket­ing in $245M deal for No­vo Nordisk's obe­si­ty ad agency Con­cen­tri­cLife

Last year
Pharma
Marketing

How Bris­tol My­er­s' buy­out of­fer for Mi­rati dwin­dled by bil­lions of dol­lars

Last year

Bris­tol My­ers pays $350M up­front for rights to heart drug Camzyos in Asia

Last year
First page Previous page 24252627282930 Next page Last page
A service from the Financial Times